Follow

BioStock: Coegin Pharma aims high in 2022

18 January 2022 - 09:07

In 2021, Coegin Pharma reached a key milestone by launching a combined phase I/II clinical trial with AVX001 in actinic keratosis patients. Moreover, the company expanded its pipeline in order to pursue cancer indications and chronic kidney disease. BioStock reached out to Coegin’s CEO Tore Duvold to hear what he had to say about the company’s achievements during 2021 and his goals for 2022.

Read the interview with Tore Duvold at biostock.se:

https://www.biostock.se/en/2022/01/coegin-pharma-aims-high-in-2022/

This is a press release from BioStock - Connecting Innovation & Capitalhttps://www.biostock.se/

Provided by: Cision
NGM Nordic SME (Sweden)
Coegin Pharma AB
Coegin Pharma specializes in molecular therapy which is further used in therapeutic treatments. Examples of diseases for which the company's solutions are used include cancer, leukemia and chronic kidney disease....
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More